Review Article

Peran sitokin dalam kerusakan saraf pada penyakit kusta: Tinjuan Pustaka

I Gusti Nyoman Darmaputra , Putu Ayu Dewita Ganeswari

I Gusti Nyoman Darmaputra
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana. Email: darmaputrakulit@yahoo.com

Putu Ayu Dewita Ganeswari
Program Pendidikan Dokter Spesialis, Department of Dermatology and Venereology, Faculty of Medicine, Universitas Udayana
Online First: December 01, 2018 | Cite this Article
Darmaputra, I., Dewita Ganeswari, P. 2018. Peran sitokin dalam kerusakan saraf pada penyakit kusta: Tinjuan Pustaka. Intisari Sains Medis 9(3). DOI:10.15562/ism.v9i3.328


Latar belakang: Kusta adalah penyakit infeksi yang menyebabkan masalah yang sangat kompleks baik dalam segi kesehatan, sosial, maupun ekonomi. Berdasarkan data WHO, jumlah kasus kusta baru pada tahun 2016 adalah sebesar 216.108 kasus (0,21 per 10.000 penduduk) dari 145 negara di dunia. Tujuan: Mengatahui peran sitokin dalam patogenesis kerusakan saraf pada penyakit kusta sehingga mempermudah proses klasifikasi kasus borderline dan memungkinkan pengobatan dini berdasarkan tipe kusta. Hasil:  Kusta adalah penyakit yang disebabkan oleh bakteri Mycobacterium leprae dan terutama menyerang saraf perifer. Manifestasi kusta dipengaruhi oleh respon imun, terutama respon imun yang diperantarain sel. Terdapat keterlibatan sitokin yang berbeda dalam kerusakan saraf pada kusta tipe pausibasiler dan multibasiler. Simpulan: Manifestasi klinis kusta dipengaruhi oleh keseimbangan sitokin-sitokin dari Th1 dan Th2.

References

Cruz, RCS., Sekula, SB., Penna, MLF. Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients. An Bras Dermatol.2017; 92(6): 761-73.

Kementerian Kesehatan RI. Profil Kesehatan Indonesia. Jakarta. 2017.

Wisnu,IM., Daili ES., Menaldi, SL. Kusta. Dalam: Djuanda,Adhi dkk.(ed). Ilmu Penyakit Kulit dan Kelamin. Edisi Ketujuh. Balai Penerbit FKUI; 2010. h.73-88

Lewis S. Leprosy. Update 4 Februari 2010. Diunduh dari http://emedicine.medscape.com/article/1104977-overview#showal

Mishra, R.S., Kumar, J. Classification. In: Kumar Kar, H., Kumar, B., editors. IAL Textbook of Leprosy. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2010. p.144-51.

Pai, W., Ganapati, R., and Rao, R. Development and Evolution of WHO MDT and Newer Treatment Regimens. In: Kumar Kar, H., Kumar, B., editors. IAL Textbook of Leprosy. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2010: p.353-67.

Kar, H.K., and Sharma, P. Leprosy Reactions. In: Kumar Kar, H., Kumar, B., editors. IAL Textbook of Leprosy. 1st ed. New Delhi: Jaypee Brothers Medical Publishers; 2010. p.269-92.

Lee, D.J., Rea, T.H., and Modlin, R.L. Leprosy. In: Goldsmith, L.A., Katz, S.I., Gilchrest, B.A., Paller, A.S., Leffell, D.J., Wolff, K., editors. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: Mc Graw Hill; 2012: p.2253-62.

Bryceson, A., and Pfaltzgraff, R.E. Immunological Complications: Reactions. In: Bryceson, A., Pfaltzgraff, R.E., editors. Leprosy. 3rd ed. London: Churcill Livingstone; 1990. p.115-26.

Widasmara, D. Penyakit Kusta Sebuah Perspektif Klinis. UB Press; 2018: h.1-17.

Baratawidjaja, K., Rengganis, I. Imunologi Dasar. Edisi X. Jakarta: Penerbit FKUI. 2012. h.219-256.

Sari, N., Amiruddin MD., Amin, S. Peran Interleukin-2 (IL-2), Interleukin-10 (IL-10), dan Tumor Necrosis Factor-α (TNF- α) pada Penyakit Kusta. MDVI. 2013; 40(1): 35-40.

Kementerian Kesehatan RI Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Pemeriksaan Bakteriologis. In: Pedoman Nasional Program Pengendalian Penyakit Kusta. 2015. p.89-98

World Health Organization (WHO). Global Leprosy Update, 2014. Weekly Epidemiological Record. 2015;62(16): 278-280.

S.H. Wang, P. Pancholi. Mycobacterial skin and soft tissue infection. Curr Infect. Dis. Rep. 2014; 16: 438.

I. Nath, C. Saini, V.L. Valluri, Immunology of leprosy and diagnostic challenges. Clin. Dermatol. 2015. p.90-8.

Masaki T, McGlinchey A, Cholewa-Waclaw J, Qu J, Tomlinson SR, et al. Innate immune response precedes Mycobacterium leprae-induced reprogramming of adult Schwann cells. Cell Reprogram. 2014; 16:9-17.

Yang D, Chen J, Shi C, Jing Z, Song N. Autophagy gene polymorphism is associated with susceptibility to leprosy by affecting inflammatory cytokines. Inflammation. 2014; 37: 593-8.

Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015; 15: 362-74.

Prameswari, R., Listiawan, MY., Rosita C. Peran TNF-α pada imunopatogenesis ENL dan Kontribusinya pada Penatalaksanaan ENL. FK Unair 2012; 24(1): 43-48.

Ramien M, Wong A, Keystone J. Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2011; 52(5): 133–5.

Lee D, Li H, Ochoa M, Tanaka M, Carbone R, Modlin R. Integrated pathways for neutrophil recruitment and inflammation in leprosy. The J of Infect Dis. 2010; 201(4): 558–69.

Listiawan MY. Perbandingan ekspresi TLR1/2, NF-κB p150/50, NF-κB p65 dan TNF-α pada makrofag penderita eritema nodosum leprosum dengan kusta multibasiler sebagai tanda aktivitas kekebalan alamiah BIK 3. 2011; 23(3): 207–15.

Jarduli, LR., Sell AM., Reis PG., et al. Role of HLA., KIR, MICA, and Cytokines Genes in Leprosy. Biomed Research International. 2013. P. 1-13

D. Turner, S. McGuiness, K. Leder, Leprosy: diagnosis and management in a developed setting, Intern Med. J.2015; 45: 109-12.

D.N. Lockwood, L. Suneetha, K.D. Sagili, et al., Cytokine and protein markers of leprosy reactions in skin and nerves: baseline results for the north Indian INFIR cohort, PLoS Negl. Trop. Dis. 2011; 5: 1327.

I. Nath, C. Saini, V.L. Valluri, Immunology of leprosy and diagnostic challenges, Clin. Dermatol. 2015; 33: 90-8.

X. Illarramendi, E. Rangel, A.M. Miranda, et al., Cutaneous lesions sensory impairment recovery and nerve regeneration in leprosy patients, Mem. Inst. Oswaldo Cruz. 2012; 107: 68-73.

Kar HK, Sharma P. Management of Leprosy In: Kar HK, Kumar B, editors. IAL Textbook of Leprosy. 1st ed. New Delhi: Jaypee Brothers Medical Publisher. 2010. p. 386–99.

Kahawita IP., Walker SL., Lockwood DNJ. Leprosy type 1 reactions and Erythema Nodosum Leprosum. An Bras Dermatol 2008; 83(1): 75-82.

Abbas AK., Licht AH. Basic Immunology. 3rd Beijing: Saunders Elsevier; 2011.

Fonseca A., Simon M., Cazzaniga R., et al. The influence of innate and adaptive immune responses on the differential clinical outcomes of leprosy. Biomed Central 2017; 6(5); 1-8.

Lastoria JC, Abreu MA. Leprosy: review of the epidemiological, clinical, and etiopathogenic aspects—part 1. An Bras Dermatol. 2014;89:205–18.

Bratschi MW, Steinmann P, Wickenden A, Gillis TP. Current knowledge on Mycobacterium leprae transmission: a systematic literature review. Lepr Rev. 2015;86:142–55.

Khadge S, Banu S, Bobosha K, van der Ploeg-van Schip JJ, Goulart IM, Thapa P, Kunwar CB, van Meijgaarden KE, van den Eeden SJ, Wilson L, et al. Longitudinal immune profiles in type 1 leprosy reactions in Bangladesh, Brazil, Ethiopia and Nepal. BMC Infect Dis. 2015;15:477.

Global leprosy update, 2014: need for early case detection. Wkly Epidemiol Rec. 2015; 90:461–74.

Motta ACF, Furini RB, Simao JCL, Ferreira MAN, Komesu MC, Foss NT. The Recurrence of Leprosy Reactional episodes could be associated with oral chronic infections and expression of serum IL-1, TNF-α, IL-6, IFN-γ and IL-10. Braz Dent J. 2010; 21(2): 158-64.

Madan, NK., Agarwal K., Chander, R. Serum cytokine profile in leprosy and its correlation clinic-histopathological profile. Lep Rev. 2011; 82: 371-382.

Ramaswari NP. Reaksi Reversal dan Eritema Nodosum Leprosum pada Penyakit Kusta. CDK. 2015; 42(9): 653-7.


No Supplementary Material available for this article.
Article Views      : 248
PDF Downloads : 192